Natera
Austin, Texas, United States · Biotechnology, Genetics, Health Care
Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the
Key facts
- Headquarters
- Austin, Texas, United States
- Employees
- 4,500
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (NTRA)
- Website
- http://www.natera.com/
- Company page
Recent activity at Natera
- : Natera, Inc. forms partnership with BGI Genomics to develop and commercialize genetic testing assays.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02):
- : SEC 8-K (5.02): Natera, Inc. appointed Thomas Lynch to its Board of Directors, increasing the size of the Board from eleven to twelve members, effective June 2, 2026. Dr. Lynch, who will serve as a Class I director with a term expiring at the 2028 annual meeting, was determined to be an independent director according to the applicable standards. His compensation will align with other non-employee directors as outlined in the Company's Amended Compensation Program, and he is also expected to receive an initial equity award expected to vest over three years. Additionally, the Company plans to enter into an Indemnification Agreement with Dr. Lynch to provide legal protections in relation to his service.
- : Natera and CytoDyn Enter Strategic Partnership to Enhance ctDNA Insights for Metastatic Colorectal Cancer Development.
- : SEC 8-K (5.02):
- : Natera acquires Foresight Diagnostics for $275 million
- : SEC 8-K (8.01): On December 5, 2025, the Company announced its acquisition of Foresight, indicating a strategic move to enhance its business offerings. This acquisition involves a deal price that may include potentially issuable shares, though specific financial terms were not disclosed. The announcement outlines potential post-closing adjustments to the purchase price, highlighting the purchase's complexity and strategic implications for future growth. The acquisition may also affect stock trading prices and shareholder dynamics due to the reallocation of shares. This acquisition event occurred on the same day as the filing, confirming its timeliness.
- : SEC 8-K (8.01): On December 4, 2025, Natera, Inc. completed the acquisition of Foresight Diagnostics Inc., a cancer diagnostics company, under an Agreement and Plan of Merger dated October 10, 2025. As part of the transaction, Natera will issue a total of approximately 1,952,565 shares of its common stock to the stockholders of Foresight, which includes 1,127,982 shares as initial consideration and an estimated 824,583 additional shares that may become issuable. This acquisition strategically enhances Natera's capabilities in molecular residual disease detection for B-cell lymphomas, positioning the company to expand its market presence in innovative cancer diagnostics. The acquisition is expected to significantly impact Natera's business operations and growth trajectory.
- : Natera, Inc. Achieves Milestone with Over 100 Publications on Signatera, a Tumor-informed MRD Test.
Natera funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2021 | Funding Round | Undisclosed |
Leadership
- Matt Love, Vice President
- Dave Peticolas, VP of Software Engineering
- Solomon Moshkevich, President
- John Fesko, Chief Business Officer
Verified email and direct lines for Natera’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Natera files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Natera in the news
- Natera’s intelligent appointment scheduling with Amazon Bedrock AgentCore - Amazon Web Services (AWS) (Aug 26, 2026)
- Natera agrees to a $8.5M settlement to end class action - Top Class Actions (Feb 23, 2022)
- Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial - Business Wire (Jun 25, 2026)
- Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform - PR Newswire (Mar 11, 2019)
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution - Nature (Apr 26, 2017)
- Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test - PR Newswire (Feb 01, 2019)
Companies similar to Natera
- Cepheid · Biotechnology, Genetics, Health Care, Health Diagnostics
- Grail · Biotechnology, Genetics, Health Care, Health Diagnostics
- Veracyte · Biotechnology, Genetics, Health Care, Health Diagnostics
- Personalis · Biotechnology, Genetics, Health Care, Health Diagnostics
- Akoya Biosciences · Biotechnology, Genetics, Health Care, Health Diagnostics
About Natera: questions and answers
What does Natera do?
Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the
Where is Natera headquartered?
Natera is headquartered in Austin, Texas, United States.
How many employees does Natera have?
Natera has about 4,500 employees.
Has Natera raised funding?
Yes. Fundz has recorded 1 funding event for Natera. The most recent, Funding Round of Undisclosed, was in Sep 2021.
Who leads Natera?
Matt Love is a Vice President at Natera.
What is the latest news on Natera?
On Sep 19, 2026, Natera, Inc. forms partnership with BGI Genomics to develop and commercialize genetic testing assays.
Is Natera a public company?
Yes. Natera is publicly traded under the ticker NTRA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy